xtmab-16
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 25, 2021 (NCT04971395)
Timeline
Indications
Mechanism of action
- TNF-alphaANTAGONIST
TNFA
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06169397 | Phase 2 | Jan 31, 2024 | Xentria, Inc. |
| NCT05890729 | Phase 1/Phase 2 (Phase 2) | Nov 10, 2023 | Xentria, Inc. |
| NCT04971395 | Phase 1 | Jun 25, 2021 | Parexel, Xentria, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xentria, Inc. | For profit | 3 | 3 | 2 | 2021 |
| Parexel | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1